Athira Market Capitalization from 2010 to 2024
| ATHA Stock | USD 0.64 0.02 3.03% |
Check Athira Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Athira Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 2.1 M, Interest Income of 2.1 M or Depreciation And Amortization of 939 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Athira financial statements analysis is a perfect complement when working with Athira Pharma Valuation or Volatility modules.
Athira | Market Capitalization |
Latest Athira Pharma's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Athira Pharma over the last few years. It is Athira Pharma's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Athira Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 25.49 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Athira Market Capitalization Regression Statistics
| Arithmetic Mean | 190,720,447 | |
| Geometric Mean | 150,567,156 | |
| Coefficient Of Variation | 86.37 | |
| Mean Deviation | 126,416,124 | |
| Median | 105,852,760 | |
| Standard Deviation | 164,731,549 | |
| Sample Variance | 27136.5T | |
| Range | 452.3M | |
| R-Value | 0.38 | |
| Mean Square Error | 24907.2T | |
| R-Squared | 0.15 | |
| Significance | 0.16 | |
| Slope | 14,156,966 | |
| Total Sum of Squares | 379910.8T |
Athira Market Capitalization History
About Athira Pharma Financial Statements
Athira Pharma stakeholders use historical fundamental indicators, such as Athira Pharma's Market Capitalization, to determine how well the company is positioned to perform in the future. Although Athira Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Athira Pharma's assets and liabilities are reflected in the revenues and expenses on Athira Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Athira Pharma. Please read more on our technical analysis and fundamental analysis pages.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company was incorporated in 2011 and is headquartered in Bothell, Washington. Athira Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out the analysis of Athira Pharma Correlation against competitors. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.